

AD _____

Award Number: DAMD17-98-1-8285

TITLE: Recombinant Polyclonal Antibody Libraries for Breast
Cancer Therapy

PRINCIPAL INVESTIGATOR: Jacqueline Sharon, Ph.D.

CONTRACTING ORGANIZATION: Boston University School of Medicine
Boston, Massachusetts 02118-2394

REPORT DATE: September 1999

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

DTIC QUALITY INSPECTED 4

20001019 032

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)

2. REPORT DATE

September 1999

3. REPORT TYPE AND DATES COVERED

Annual (1 Sep 98 - 31 Aug 99)

4. TITLE AND SUBTITLE

Recombinant Polyclonal Antibody Libraries for
Breast Cancer Therapy

5. FUNDING NUMBERS

DAMD17-98-1-8285

6. AUTHOR(S)

Jacqueline Sharon, Ph.D.

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)

Boston University School of Medicine
Boston, Massachusetts 02118-23948. PERFORMING ORGANIZATION
REPORT NUMBER

E-MAIL:

jsharon@bu.edu

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)

U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-501210. SPONSORING / MONITORING
AGENCY REPORT NUMBER

11. SUPPLEMENTARY NOTES

12a. DISTRIBUTION / AVAILABILITY STATEMENT

Approved for public release; distribution unlimited

12b. DISTRIBUTION CODE

13. ABSTRACT (Maximum 200 Words)

This project proposes the development of a recombinant polyclonal antibody specific for the human breast carcinoma cell line BT-20. The proposed library would target multiple epitopes on the human cell line and also provide the genes necessary for the unlimited perpetuation of the defined antibody mixture. Ultimately, such antibody libraries could be used for treatment and diagnosis of breast cancer in humans. In the present study, V region genes for construction of a polyclonal Fab phage display library were obtained from the spleen, bone marrow, and intestine of a BALB/c mouse that had been immunized with BT-20 cells. The light and heavy chain V region genes were linked by reverse transcription-polymerase chain reaction (RT-PCR) and cloned into a bidirectional phagemid vector to express an Fab-displaying phage library. This library was then selected for binding to BT-20 cells. Direct and inhibition ELISA showed that the selected Fab phage display library bound specifically to BT-20 cells, and that this binding could be inhibited by BT-20 as well as by other human breast cancer cell lines, but not by sheep red blood cells. These results demonstrate that the first phase of generating a polyclonal antibody library can be done successfully.

14. SUBJECT TERMS

Breast Cancer

15. NUMBER OF PAGES 20

16. PRICE CODE

17. SECURITY CLASSIFICATION
OF REPORT

Unclassified

18. SECURITY CLASSIFICATION
OF THIS PAGE

Unclassified

19. SECURITY CLASSIFICATION
OF ABSTRACT

Unclassified

20. LIMITATION OF ABSTRACT

Unlimited

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)

Prescribed by ANSI Std. Z39-18

298-102

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

___ Where copyrighted material is quoted, permission has been obtained to use such material.

___ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

___ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

N/A In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

X For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

N/A In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

N/A In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

N/A In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.


 9/21/99
PI - Signature Date

TABLE OF CONTENTS

	<u>section</u>	<u>page</u>
(1)	Front Cover	1
(1)	Standard Form (SF) 298, Report Document Page	2
(2)	Foreword	3
(3)	Table of Contents	4
(4)	Introduction	5
(5)	Body	6
(6)	Key Research Accomplishments	8
(7)	Reportable Outcomes	8
	Conclusions	8
	References	9
	Appendix: Figure Legends	10
	Figures 1-6	12-17

(4) INTRODUCTION:

As an immunotherapeutic approach to breast cancer, we set out to develop recombinant polyclonal antibody libraries that would target malignant cells. Polyclonal antibody libraries combine the advantages of targeting multiple antigenic determinants (low likelihood of antigen 'escape variants') with the advantages of using monoclonal antibodies (unlimited supply of standardized reagents, and the availability of the genetic material for desired manipulations). In the present study, we have used a bidirectional *lPPI* cassette containing the Zeocin selectable marker (1, 2) to achieve efficient expression of Fab-displaying phage for generating a specific polyclonal Fab phage display library to the human breast carcinoma cell line BT-20.

We have previously described a system for generation of recombinant polyclonal antibody libraries (3, 4). This system involves the cloning of VL-VH region gene pairs into a bidirectional phage display vector for Fab expression, such that the VL and VH region genes of each pair are in opposite (head to head) transcriptional orientations ($\leftarrow\rightarrow$). Because the phage display vector is circular, the vector library can be opened with restriction enzymes between VL and VH to insert a bidirectional leader-promoter-promoter-leader (*lPPI*) cassette that allows expression of Fab on the phage surface. Furthermore, a subpopulation of Fab-phage can be selected for binding to a desired antigen or polyantigen (a multi-antigen particle such as a mammalian or microbial cell). The VL-VH region gene pairs of the selected phage subpopulation are then transferred, in mass, from the phage display vector to a bidirectional mammalian expression vector to produce whole antibodies that can mediate effector functions.

(5) BODY:

The human breast adenocarcinoma cell line BT-20 was chosen for generation of an anti-human breast cancer polyclonal antibody library (PCAL) because of the ability of BT-20 cells to form tumors in immunodeficient nude mice (ATCC catalog, Rockville, MD). This affords a system for *in vivo* efficacy testing of the library. V region genes for construction of a polyclonal Fab phage display library to BT-20 cells were obtained from a Balb/c mouse that had been immunized with BT-20 cells. The serum antibody titer was assessed, by ELISA on fixed BT-20 cells, at various days post primary immunization. As shown in Fig. 1, the serum titer rose to almost 17,000 during the immunization. Immunoblot analysis for reactivity of the antiserum with BT-20 membranes showed recognition of a wide variety of BT-20 antigens (Fig. 2), indicative of the polyclonality of the antibodies. (The antiserum also reacted with another human breast carcinoma cell line, Hs 578T, see Fig. 2)

Total RNA was prepared from spleen, bone marrow, and intestine of the sacrificed animal, and linked VL-VH region gene pairs were generated by RT-PCR as previously described (5) except that V region genes of IgA H chains (α) were also amplified, in addition to IgG and IgM H chains. The linked VL-VH region genes were ligated into the phh3 vector (see Fig. 3), resulting in a phh3-VL-VH library of about 2×10^7 members. For expression of Fab on the phage surface, the prokaryotic bidirectional leader/promoter cassette containing the Zeocin selectable marker (*lPZeoPl*) was inserted between VL and VH, generating the Fab phage display library of vectors (phh3-VL-*lPZeoPl*-VH, see Fig. 3).

To select an Fab phage sublibrary that reacts with the BT-20 carcinoma cells, phage (10^{11} cfu) were subjected to two consecutive rounds of panning on fixed BT-20 cells (with amplification of the phage by infection into bacteria after each pan). The first pan yielded 8×10^4 cfu of bound/eluted phage whereas the second pan yielded 3×10^6

cfu of bound/eluted phage, a 37.5-fold increase over the first pan. This increase indicated a sequential enrichment in anti-BT-20 Fab phage during the panning procedure. Analysis of the unpanned and panned Fab phage libraries by ELISA on fixed BT-20 cells confirmed this sequential enrichment, showing that the second pan library binds better than the first pan library which, in turn, binds better than the unpanned library (Fig. 4). Both the unpanned and second pan libraries were determined to be polyclonal by nucleotide sequence analysis of the VL and VH region genes of individual clones (data not shown).

To confirm the specificity of the second pan Fab phage library for BT-20 cells, the library was tested in a "criss-cross" inhibition ELISA in conjunction with a panned anti-sheep red blood cells (anti-SRBC) Fab phage library. BT-20 membranes inhibited the binding of the anti-BT-20 phage library to solid phase BT-20 cells in a dose-dependent manner (Fig. 5A) but not of the anti-SRBC phage library to solid phase SRBC ghosts (Fig. 5B). Conversely, SRBC ghosts inhibited the binding of the anti-SRBC phage library to solid phase SRBC ghosts in a dose-dependent manner (Fig. 5B) but not of the anti-BT-20 phage library to solid phase BT-20 cells (Fig. 5A). Thus, both the anti-BT-20 and anti-SRBC libraries showed specificity for their immunizing/panning polyantigens.

The second pan anti-BT-20 library was then tested in another inhibition ELISA to determine if it can react with other human breast carcinoma cell lines. As shown in Fig. 6, membrane preparations of both the Hs 578T and MCF-7 human breast carcinoma cell lines inhibited the binding of the second pan anti-BT-20 library to solid phase BT-20 cells, in a dose-dependent manner. Thus, the anti-BT-20 Fab phage display library can bind to other breast carcinoma cell lines.

The results presented here demonstrate that a polyclonal Fab phage display library specific for human breast carcinoma cells can be generated using our bidirectional vector system. Such libraries, after suitable negative selection to eliminate major reactivities against normal tissue, could be transferred in mass to our

bidirectional mammalian expression vector for production of libraries of whole antibodies (3, 4, 5) with constant regions of any desired isotype or species. Polyclonal antibody libraries will mediate effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), and are expected to be useful for breast cancer therapy, as well as diagnosis.

(6) KEY RESEARCH ACCOMPLISHMENTS

- Mice were immunized with human breast carcinoma cell line BT-20
- An original Fab phage library was generated from the V region genes obtained from an immune mouse
- An Fab phage display library was generated
- The Fab phage display library was positively selected on the BT-20 human breast carcinoma cell line, and shown to be specific and polyclonal

(7) REPORTABLE OUTCOMES

1 manuscript is in preparation

CONCLUSIONS

In the present study, V region genes for construction of a polyclonal Fab phage display library were obtained from the spleen, bone marrow, and intestine of a Balb/c mouse that had been immunized with BT-20 cells. The light and heavy chain V region genes

were linked by reverse transcription-polymerase chain reaction (RT-PCR) and cloned into a bidirectional phagemid vector to express an Fab-displaying phage library. This library was then selected for binding to BT-20 cells. Direct and inhibition ELISA showed that the selected Fab phage display library bound specifically to BT-20 cells, and that this binding could be inhibited by BT-20 as well as by other human breast cancer cell lines, but not by sheep red blood cells. These results demonstrate that the first phase of generating a polyclonal antibody library can be done successfully. Recombinant polyclonal antibody libraries could be used for treatment and diagnosis of breast cancer in humans.

REFERENCES

1. J. Bérdy, A. A. Aszalos, M. Bostian, K. L. McNitt, in *CRC Handbook of antibiotic compounds* J. Berdy, Ed. (CRC Press, Boca Raton, 1980).
2. A. Gatignol, H. Durand, G. Tiraby, *FEBS Lett.* **230**, 171-175 (1988).
3. S. Sarantopoulos, C. Y. Y. Kao, W. Den, J. Sharon, *Journal of Immunology* **152**, 5344-5351 (1994).
4. W. Den, S. R. Sompuram, S. Sarantopoulos, J. Sharon, *Journal of Immunological Methods* **222**, 45-57 (1999).
5. S. Sarantopoulos, S. Petersen-Mahrt, J. Sharon, *Submitted for publication* (1999).

APPENDIX

FIGURE LEGENDS

Fig. 1 Serum antibody response of Balb/c mouse immunized with BT-20 cells. Serum titer was defined as the last dilution that gave an OD 405 reading of at least 0.6. BT-20 cells were grown to confluence in a 96 well plate, washed, and fixed with 4% paraformaldehyde for 20 minutes. ELISA procedure was performed on the fixed cells that were first blocked with 3% BSA and 1:2 dilutions of serum was added. The plate was developed with a rabbit anti-mouse Ig (Sigma, St Louis, MO) and an alkaline phosphatase-conjugated anti-rabbit antibody (Promega, Madison, WI). The ELISA results were read at 405 nm.

Fig. 2 Western analysis on BT-20 and Hs 578T membrane preps for reactivity to pre-immune and immune sera.

Fig. 3 Schematic diagram of Fab-encoding phagemid vectors. *phh3-VL-lpZeoPl-VH* is generated by insertion of the *lpZeoPl* cassette into *phh3-VL-VH*. The direction of transcription is indicated by arrow heads on promoters and V region genes. P, promoter; *l*, leader sequence; *lmod*, leader sequence with modified nucleotide sequence; Stop, translation termination. Amino acids encoded by the vectors are shown in one letter code.

Fig. 4 ELISA of the mouse anti-BT-20 phage on BT-20 cells. As negative control, phage encoding no Fab on its surface was used, and the value of 0.755 was subtracted from the graphed values as background binding of phage.

Fig. 5 Inhibition ELISA on **A)** BT-20 membrane-coated ELISA plate using Balb/c anti-BT-20 Pan II phage ; and **B)** SRBC-coated ELISA plates using Balb/c anti-SRBC Pan II phage. Phage were preincubated with either 0, 0.1, 1, or 4 μ g of either SRBC ghosts or crude BT-20 membranes for one hour prior to adding to the plate.

Fig. 6 Inhibition ELISA on other breast carcinoma cell membranes.




Fig. 1




Fig. 2




Fig. 3






Fig. 4

A**Balb/c anti-BT-20 Pan II phage inhibition****B****Balb/c anti SRBC phage inhibition****Fig. 5**




Fig. 6